TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Energy Instruments and Stapling Device to Dissect Intersegmental Plane in Segmentectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Age: 18 to 70 years old; 2. Pulmonary nodules or GGO found in chest CT examination, and conform with indications for segmentectomy mentioned in NCCN guidelines:~  1. Poor pulmonary reserve or other major comorbidity that contraindicates lobectomy;~ 2. Peripheral nodule ≤2 cm with at least one of the following:~  <!-- -->~  1. Pure (Adenocarcinoma in situ) AIS histology;~ 2. Nodule has ≥50% ground-glass appearance on CT;~ 3. Radiologic surveillance confirms a long doubling time (≥400 days). 3. Normal in preoperative tests, such as blood routine examination, liver function, renal function, coagulation function, etc.~  4. ASA score: Grade I-III. 5. Patients who can coordinate the treatment and research and sign the informed consent.~Exclusion Criteria:~* 1. Patients have history of malignant tumor, or have accepted neoadjuvant chemotherapy and(or) radiotherapy.~  2. Patients have comorbidities in cardiovascular, kidney, lung or hematopoietic system, who cannot tolerate the surgery.~  3. Psychiatric patients。 4. Patient have history of chest trauma or surgery on ipsilateral chest.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Energy Instruments Group (Type: EXPERIMENTAL): All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use energy instruments dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
- Stapling Device Group (Type: EXPERIMENTAL): All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use stapling device to dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with biomarker negative stable or unstable angina pectoris~* Written informed consent~* In women with childbearing potential a pregnancy test is obligatory~Exclusion Criteria:~* Age \< 18 years and \>80 years~* ST-elevation MI~* Elevated cardiac biomarkers~* Subjects with known contraindications to clopidogrel treatment, which are hypersensitivity to the drug substance or any component of the product and active pathological bleeding such as peptic ulcer or intracranial hemorrhage and with known severe liver disease (Child Pugh Class C)~* Subjects with known contraindications to prasugrel treatment, which are hypersensitivity to the drug substance or any component of the product, active pathological bleeding such as peptic ulcer or intracranial hemorrhage and a history of prior transient ischemic attack (TIA) or stroke and with known severe liver disease (Child Pugh Class C)~* Chronic therapy on potent P2Y12 receptor inhibitors (ticagrelor, prasugrel)~* Pre-treatment with a loading dose of either clopidogrel, prasugrel or ticagrelor~* Simultaneous participation in another clinical trial that involves the administration of an investigational medicinal drug within 30 days prior to the start of this clinical trial~* Major surgeries in the last 6 weeks and planned surgeries within the next 6 weeks (per decision of the treating physician)~* Active bleeding~* Known or persistent abuse of medication, drugs or alcohol~* Current or planned pregnancy or nursing women, women 90 days after childbirth. Females of childbearing potential, who do not use and are not willing to use medically reliable methods of contraception for the entire study duration (such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices) unless they are surgically sterilized / hysterectomized or there are any other criteria considered sufficiently reliable by the investigator in individual cases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: EXPERIMENTAL): single-dose loading with 60 mg of prasugrel pre PCI
- Clopidogrel (Type: ACTIVE_COMPARATOR): loading with 600 mg of clopidogrel pre PCI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mild Hypothermia and Supplemental Magnesium Sulfate Infusion in Severe Traumatic Brain Injury (TBI) Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult males or females ≥ 18 years of age~2. Subjects with Traumatic Brain Injury and a post-resuscitation Glasgow Coma Score (GCS) ≤ 8~3. In-hospital and screened within 7 hours of injury.~4. Able to obtain legally effective written consent from authorized representative~5. Patients who are intubated and on mechanical ventilation~6. Admitted to ICU~Exclusion Criteria:~1. Bladder or rectal core temperature below 32C (89.6F) upon admission~2. Clinical brain death~3. Patients with open abdomens.~4. Multiple orthopedic injuries (\> 2 long bone fractures)~5. Persistent hypotension (systolic blood pressure \< 90mmHg)~6. Persistent hypoxia (O2 Saturation \< 94%)~7. Persistent metabolic acidosis (Lactic acid \> 5 mmol/L, arterial pH \< 7.25)~8. Positive serum pregnancy test~9. Cardiac arrhythmia with deleterious hemodynamic effects; heart block or myocardial damage (as shown on ECG)~10. History of abnormal renal function~11. Significant Co-morbidity (i.e. CAD;COPD; severe coagulopathy)~12. Pediatric patients (\< 18 years old)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Therapy (Type: NO_INTERVENTION): None
- Hypothermia (Type: EXPERIMENTAL): Subjects will have their core body temperatures lowered to 34C.
- Hypothermia plus supplemental magnesium sulfate infusion (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of relapsing-remitting multiple sclerosis (RRMS)~* ability to consent and a written approval~* First acute ON attack to the fit eye within 30 days before screening~* Age 18 - 55 years at screening~* EDSS ≤ 6.0~* No MS Attack except for ON in the last 30 days before screening~* No immunomodulatory therapy for at least three Months (before randomization), or~* strong immunomodulatory therapy with interferon beta or glatiramer acetate for at least 6 months~* visus in the affected eye at least 0.1~* latency of Conventional VEP in the affected eye~  * = 115 ms or difference\> = 15 ms to the opposite side at a Study at least 4 but no more than 6 weeks after Onset of clinical symptoms~* At least 2 T2 lesions typical of MS in a previous MRI~Exclusion Criteria:~* other MS course than RRMS~* any condition which could interfere or prevent the MRI study or other investigations~* known allergy or intolerance, or other contraindication against Gd-DTPA~* Patients with known contraindications to treatment with fingolimod (Gilenya ®) or interferon beta-1b Extavia ®~* Competing diseases which could affect visual functions such as diabetic, retinopathy, glaucoma, retinal detachment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod (Gilenya®) (Type: EXPERIMENTAL): 0,5 mg once a day in the morning, oral
- Interferon beta-1b (Extavia®) (Type: ACTIVE_COMPARATOR): every second day, s.c.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Blood Flow Restriction Therapy in Patellofemoral Pain Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA class I-II~* Diagnosed with patellofemoral pain syndrome~Exclusion Criteria:~* Patients with confirmed radiographic evidence explaining knee pain~* Legally incompetent or mentally impaired (e.g. minors, Alzheimer's subjects, dementia, etc.)~* Younger than 18 years of age or older than 65~* Any patient considered a vulnerable subject~* Patients with impaired circulation, peripheral vascular compromise, Previous revascularization of the extremity, or severe hypertension~* Patients with Sickle cell anemia or venous thromboembolism~* Patients with Sickle cell anemia or venous thromboembolism~* Patients with cancer or Lymphectomies~* Patients with increased intracranial pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Patients with Patellopain syndrome with Cuff (Type: EXPERIMENTAL): Patient will be prescribed to 6 weeks of physical therapy with a cuff around the affected leg during exercises
- Patients with Patellopain syndrome with Placebo Cuff (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven squamous cell skin carcinoma~* Recipient of a renal organ transplant at least one year prior to study enrollment~* Receiving a CNI for at least 6 months prior to diagnosis of skin cancer~* No current evidence of graft rejection, except low-grade, chronic graft rejection~* Measurable disease by caliper measurement~* Life expectancy \> 6 months~* Age of at least 18 years~* Adequate organ and marrow function as determined by ANC, HGB, PLT, Total Bili, AST, and creatinine clearance~* Ability to understand/willingness to sign a written informed consent form~Exclusion Criteria:~* Inability to give informed consent~* Major surgery within 4 week prior to starting study drug~* Chronic or non-healing open wounds~* Pregnant and nursing women~* Women and men of child-bearing potential must agree to use adequate contraception prior to study entry and for the study duration~* Prior use of an mTOR inhibitor~* Pre-existing clinically significant cardiac, hepatic, pulmonary, or renal dysfunction~* HIV-positive patients~* Proteinuria (\> 1 gram)~* Prior or current history of uncontrolled hyperlipidemia (cholesterol \> 302 mg/dl or triglycerides 354 mg/dl~* Currently receiving any investigational agents~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to sirolimus (mTOR inhibitors)~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sirolimus treatment (Type: EXPERIMENTAL): Patients will receive sirolimus 5 weeks prior to removal of squamous cell skin carcinoma. After the 5 weeks of treatment, nephrology will determine/manage each patient's immunosuppressant therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~All of the following conditions must apply to the prospective patient at screening prior to participation:~* Histologically verified prostate cancer, and either currently on Zoladex or without any current or no past usage of any ADT~* Between 18 and 75 years of age~* Capable of reading and understanding Norwegian, and able to provide informed consent~* Treating oncologist/ study medical doctor´s (KMR) approval for participation~* Signed informed consent must be obtained and documented according to Good Clinical Practice (GCP), and national/local regulations.~Exclusion Criteria:~Patients will be excluded from the study if they meet any of the following criteria:~* Routine resistance training (\>1 weekly session, last six months)~* Treated with Warfarin, or if seponation of acetylsalicylic acid is not recommended~* Conditions where heavy resistance exercise is contraindicated:~  * Unregulated hypertension~ * Unstable angina pectoris~ * Recent myocardial infarction (\<1 year)~ * Cardiac arrhythmia~ * Chronic obstructive pulmonary disease~ * Severe asthma~ * Recent stroke (\<1 year)~ * Epilepsy~ * Insulin-dependent diabetes mellitus~ * Unstable bone lesions with increased risk of fractures~* Conditions where patients ability to complete the training sessions is challenged:~  * Uncontrolled pain~ * Severe arthritis~ * Scheduled hip or knee replacement~ * Pathologic fractures last six months~ * Amputations~ * Walker or wheelchair user~* Mentally incompetent conditions:~  * Severe anxiety or depression~ * Dementia~ * Known alcoholism or substance abuse~ * Mentally retarded

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ADT group (Type: EXPERIMENTAL): Prostate cancer patients currently receiving androgen deprivation therapy (Zoladex)
- No-ADT group (Type: NO_INTERVENTION): Prostate cancer patients without any history of receiving any form of androgen deprivation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Arm Cycling and Leg Cycling on Postprandial Blood Glucose Levels in Healthy Persons

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Apparently healthy persons~* Age 18 years or above~Exclusion Criteria:~* Cardiovascular diseases~* Pulmonary diseases~* Metabolic diseases~* Other contraindications to exercise

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: t

Study Arms:
- Arm Cycling (Type: EXPERIMENTAL): Arm cycling on an arm crank ergometer for 20 minutes at light to moderate intensity. 30 minutes before the exercise, participants will consume 60g of carbohydrates mixed with plain water.
- Leg Cycling (Type: EXPERIMENTAL): Leg cycling on a leg cycling ergometer for 20 minutes at light to moderate intensity. 30 minutes before the exercise, participants will consume 60g of carbohydrates mixed with plain water.
- Sitting (Type: PLACEBO_COMPARATOR): Participants will remain seated after carbohydrates consumption.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with tuberculosis diagnosis, HIV positive.~* Agreement to avoid not allowed drugs during the trial, agreement to participate in the study (informed consent)~Exclusion Criteria:~* Active liver disease~* Pregnancy or breast feeding~* CD4 counts \>350

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EFAVIRENZ 800mg (Type: EXPERIMENTAL): Efavirenz 800 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
- EFAVIRENZ 600mg (Type: ACTIVE_COMPARATOR): Efavirenz 600 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Refractory Urge Incontinence and Botox Injections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult women~* Detrusor overactivity incontinence confirmed by urodynamic testing~* Symptoms refractory to standard first- and second-line treatments~* 6 or more urge incontinence episodes on 3-day bladder diary~* Normal neurological examination~Exclusion Criteria:~* Urinary retention~* Allergy to Botox (Botulinum Toxin A)~* Previous bladder treatment with Botox (Botulinum Toxin A) in the past year~* Pregnancy or planning pregnancy within next year~* Neurologic disease with impaired neurotransmission

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Botox A (Type: EXPERIMENTAL): up to two injections of 200 Units of intra-detrusor Botulinum Toxin A , which must be separated by at least eight weeks and no more than 52 weeks
- Placebo (Type: PLACEBO_COMPARATOR): up to two injections of inactive injection (carrier saline), which must be separated by at least eight weeks and no more than 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Verb Network Strengthening Treatment (VNeST) on Word Finding in Aphasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aphasia and subjective experience of word finding difficulties~* Diagnosed left-hemisphere stroke at least six months post-onset~* With correction, sufficient hearing and vision to be able to participate in training and assessment~* Primarily speaking Swedish for at least the last 15 years~Exclusion Criteria:~* Other neurological injury or disease~* Moderately or severely impaired comprehension~* Moderate-severe apraxia of speech or dysarthria which may interfere with assessment~* Participation in any other speech-language treatment during the study~* Active substance dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Telepractice treatment (TP-T) (Type: EXPERIMENTAL): Participants will receive 30 hours of training, 2-3 times a week in ten weeks using Verb Network Strengthening Treatment (VNeST).~Treatment will be done with a speech-language pathologist providing the therapy through an online platform.
- In-clinic treatment (IC-T) (Type: ACTIVE_COMPARATOR): Participants will receive 30 hours of training, 2-3 times a week in ten weeks using Verb Network Strengthening Treatment (VNeST).~Treatment will be done with a speech-language pathologist providing the therapy in person at a clinic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility